Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,934 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01640405 | Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells(VISNU-1) | completed | Phase 3 | 350 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT00820222 | Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer | completed | Phase 3 |
| 540 |
| Novartis PharmaceuticalsINDUSTRY |
| 14 |
| Apr 2, 2019 |
| clinicaltrials |
| NCT02117479 | Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | terminated | Phase 3 | 321 | Incyte CorporationINDUSTRY | 12 | Mar 26, 2019 | clinicaltrials |
| NCT02472145 | An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | completed | Phase 2 / Phase 3 | 326 | Janssen Research & Development, LLCINDUSTRY | 14 | Mar 19, 2019 | clinicaltrials |
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | terminated | Phase 2 / Phase 3 | 545 | Boehringer IngelheimINDUSTRY | 27 | Mar 18, 2019 | clinicaltrials |
| NCT01243944 | Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) | completed | Phase 3 | 222 | Incyte CorporationINDUSTRY | 18 | Mar 6, 2019 | clinicaltrials |
| NCT01502696 | Adjuvant PEG Intron in Ulcerated Melanoma | unknown | Phase 3 | 1,200 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Mar 4, 2019 | clinicaltrials |
| NCT00418028 | Standard Versus Continuous Capecitabine in Advanced Breast Cancer | completed | Phase 2 / Phase 3 | 195 | Hospital San Carlos, MadridOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT01881230 | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)(tnAcity) | completed | Phase 2 / Phase 3 | 191 | CelgeneINDUSTRY | 12 | Feb 21, 2019 | clinicaltrials |
| NCT01523587 | LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy | completed | Phase 3 | 795 | Boehringer IngelheimINDUSTRY | 23 | Feb 15, 2019 | clinicaltrials |
| NCT02409355 | A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111) | terminated | Phase 3 | 8 | Hoffmann-La RocheINDUSTRY | 14 | Feb 15, 2019 | clinicaltrials |
| NCT02364999 | A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC | completed | Phase 3 | 719 | PfizerINDUSTRY | 27 | Feb 7, 2019 | clinicaltrials |
| NCT01020448 | Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer(Triptocare) | completed | Phase 3 | 339 | IpsenINDUSTRY | 10 | Jan 30, 2019 | clinicaltrials |
| NCT01633060 | A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi(BELLE-3) | terminated | Phase 3 | 432 | Novartis PharmaceuticalsINDUSTRY | 22 | Jan 30, 2019 | clinicaltrials |
| NCT00678392 | Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer | completed | Phase 3 | 723 | PfizerINDUSTRY | 22 | Jan 9, 2019 | clinicaltrials |
| NCT01564784 | A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia | completed | Phase 3 | 326 | PfizerINDUSTRY | 20 | Jan 9, 2019 | clinicaltrials |
| NCT00574873 | Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML | completed | Phase 3 | 502 | PfizerINDUSTRY | 29 | Jan 8, 2019 | clinicaltrials |
| NCT01987505 | MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma | completed | Phase 3 | 140 | Hoffmann-La RocheINDUSTRY | 1 | Dec 26, 2018 | clinicaltrials |
| NCT00960440 | Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors | completed | Phase 3 | 399 | PfizerINDUSTRY | 14 | Dec 19, 2018 | clinicaltrials |
| NCT01193257 | Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer. | completed | Phase 3 | 1,099 | Millennium Pharmaceuticals, Inc.INDUSTRY | 14 | Dec 19, 2018 | clinicaltrials |
| NCT00789373 | A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 939 | Eli Lilly and CompanyINDUSTRY | 15 | Dec 14, 2018 | clinicaltrials |
| NCT02785900 | Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia(CASCADE) | terminated | Phase 3 | 240 | Seagen Inc.INDUSTRY | 16 | Dec 12, 2018 | clinicaltrials |
| NCT00974311 | Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy(AFFIRM) | completed | Phase 3 | 1,199 | PfizerINDUSTRY | 15 | Dec 11, 2018 | clinicaltrials |
| NCT00805194 | LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer | completed | Phase 3 | 1,314 | Boehringer IngelheimINDUSTRY | 27 | Dec 5, 2018 | clinicaltrials |
| NCT01200758 | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma | completed | Phase 3 | 410 | Hoffmann-La RocheINDUSTRY | 30 | Nov 27, 2018 | clinicaltrials |
| NCT01980875 | Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 57 | Gilead SciencesINDUSTRY | 8 | Nov 19, 2018 | clinicaltrials |
| NCT01980888 | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 311 | Gilead SciencesINDUSTRY | 13 | Nov 19, 2018 | clinicaltrials |
| NCT01732913 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas(Yosemite) | terminated | Phase 3 | 295 | Gilead SciencesINDUSTRY | 19 | Nov 16, 2018 | clinicaltrials |
| NCT01732926 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas(Bridalveil) | terminated | Phase 3 | 475 | Gilead SciencesINDUSTRY | 15 | Nov 16, 2018 | clinicaltrials |
| NCT00375674 | A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer(S-TRAC) | completed | Phase 3 | 674 | PfizerINDUSTRY | 22 | Sep 21, 2018 | clinicaltrials |
| NCT01010061 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT01998880 | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT02053610 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT00984282 | Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer | completed | Phase 3 | 417 | BayerINDUSTRY | 18 | Sep 13, 2018 | clinicaltrials |
| NCT00332202 | PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin | completed | Phase 3 | 758 | Eli Lilly and CompanyINDUSTRY | 25 | Sep 10, 2018 | clinicaltrials |
| NCT01191801 | Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML(VALOR) | completed | Phase 3 | 711 | Sunesis PharmaceuticalsINDUSTRY | 15 | Aug 22, 2018 | clinicaltrials |
| NCT02681432 | Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer(hipecova) | unknown | Phase 3 | 60 | PEDRO VILLAREJO CAMPOSOTHER | 1 | Aug 21, 2018 | clinicaltrials |
| NCT00122681 | Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 | completed | Phase 3 | 18,729 | GlaxoSmithKlineINDUSTRY | 14 | Aug 20, 2018 | clinicaltrials |
| NCT01026142 | A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) | completed | Phase 3 | 452 | Hoffmann-La RocheINDUSTRY | 23 | Aug 14, 2018 | clinicaltrials |
| NCT00692770 | Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)(STORM) | completed | Phase 3 | 1,114 | BayerINDUSTRY | 28 | Aug 8, 2018 | clinicaltrials |
| NCT00333788 | Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease(Welcome2) | completed | Phase 3 | 233 | UCB PharmaINDUSTRY | 12 | Aug 7, 2018 | clinicaltrials |
| NCT01482962 | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma | completed | Phase 3 | 271 | Millennium Pharmaceuticals, Inc.INDUSTRY | 31 | Jul 31, 2018 | clinicaltrials |
| NCT01767155 | Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer(ZoptEC) | completed | Phase 3 | 511 | AEterna ZentarisINDUSTRY | 22 | Jul 31, 2018 | clinicaltrials |
| NCT03606863 | Peripheral Parenteral Nutrition vs Conventional Fluid in Colorectal Resection in ERAS | unknown | Phase 3 | 200 | Antonio Arroyo SebastianOTHER | 1 | Jul 31, 2018 | clinicaltrials |
| NCT00426361 | Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects | completed | Phase 3 | 751 | GlaxoSmithKlineINDUSTRY | 3 | Jul 20, 2018 | clinicaltrials |
| NCT01006252 | A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma(SUMMIT-1) | terminated | Phase 3 | 336 | Eli Lilly and CompanyINDUSTRY | 18 | Jul 17, 2018 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials